Business Wire

NY-CELONIS

14.5.2024 08:01:35 CEST | Business Wire | Press release

Share
Celonis Recognized as a Leader for Second Consecutive Year in 2024 Gartner® Magic Quadrant™ for Process Mining Platforms

Celonis, the global leader in Process Mining, announced today that it has been named a Leader in the Gartner Magic Quadrant for Process Mining Platforms for the second time since the category's inception last year. Celonis was evaluated and placed in the Leaders’ Quadrant, being positioned highest on the Ability to Execute axis and advancing to the furthest spot on the Completeness of Vision axis once again.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513067064/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Celonis is a Leader in the 2024 Gartner Magic Quadrant for Process Mining Platforms, placed highest on the Ability to Execute and highest on Completeness of Vision. (Graphic: Business Wire)

“The pace of change keeps accelerating - new technologies keep emerging, customer expectations keep rising, and the need for greater efficiency keeps increasing. To succeed, organizations need solutions that help them address all these demands, and most importantly create meaningful value,” said Alex Rinke, co-CEO and co-founder of Celonis. “Celonis gives companies a common language for how their business runs and provides the context to enable technologies like AI and automation to become effective. For us, being named a Leader for the second consecutive year in the Gartner Magic Quadrant for Process Mining Platforms reinforces our commitment to make processes work for people, companies and the planet. We are proud to receive this recognition and will continue to build the future of process intelligence together with our customers, partners and fellow Celonauts who have embraced our vision and keep pushing process mining to realize its full potential.”

“Process mining has become an essential enterprise solution for adapting to an uncertain world and driving transformation at speed and scale,” said Daniel de Rooij, SVP Digital Transformation and CIO Hygiene at Reckitt, a global consumer products company with well-known brands such as Finish dishwasher tablets, Lysol disinfectant, and Nurofen painkillers. “With advancements like object-centric process mining and the Process Intelligence Graph, Celonis’ platform provides us with the unique process intelligence that we need to optimize IT operations, deliver value to the business faster, and drive disruptive innovation with emerging technologies like generative AI.”

Celonis enables customers to identify and capture hidden value, empower their people with actionable insights, and help them more effectively leverage technologies like AI and automation to optimize their processes. At the core of the Celonis Platform is the Process Intelligence Graph (PI Graph), an extensible digital twin of the business based on a standardized, object-centric data model. This twin is system-agnostic and without bias. The PI Graph adds business context to this process digital twin with out-of-the-box KPI definitions and improvement opportunities, such as how delivery blocks impact on-time delivery rate. Sitting at the heart of the Celonis platform, the PI Graph allows us to create capabilities that embed AI in ready-to-use solutions. For example, the Process Copilot chatbot turns natural language requests into process insights, and the AI-powered Duplicate Checker App helps keep customers from paying invoices twice. Using our Machine Learning (ML) Workbench customers and partners can create their own AI solutions in Celonis or feed data into their existing AI tools using our Intelligence API.

The platform also provides advanced process modeling functionality. In 2023, Celonis acquired Symbio, a provider of AI-driven Business Process Management (BPM) software. The integration of Symbio’s capabilities into the Celonis platform enables customers to not only mine their processes and identify value opportunities, but also design their ideal process using a modern, AI-assisted process modeling solution. Customers can also ensure their processes stay on the straight and narrow with the Process Adherence Manager and track the business impact of their process improvement work with the Transformation Hub.

Notes to editors

The 2024 Gartner Magic Quadrant on Process Mining Platforms is available here.
Find more information on Process Mining and the Celonis Process Intelligence Platform here.

Gartner, Magic Quadrant for Process Mining Platforms, Marc Kerremans, David Sudgen, Nick Duffy, 29 April 2024

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Celonis

Since 2011, Celonis has helped thousands of the world’s largest and most esteemed companies yield immediate cash impact, radically improve customer experience, and reduce carbon emissions. Its Process Intelligence platform uses industry-leading process mining technology and AI to present companies with a living digital twin of their end-to-end processes. For the first time, everyone in an organization has a common language for how the business runs, visibility into where value is hiding, and the ability to capture it. Celonis is headquartered in Munich, Germany and New York City, USA with more than 20 offices worldwide.

© 2024 Celonis SE. All rights reserved. Celonis and the Celonis “droplet” logo are trademarks or registered trademarks of Celonis SE in Germany and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240513067064/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye